Status:
COMPLETED
A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients
Lead Sponsor:
Central South University
Conditions:
Schizophrenia
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
The goal of the study is to investigate whether adding sulforaphane will benefit the negative symptoms and cognitive function in individuals who have schizophrenia. This study will compare the sulfor...
Detailed Description
This study will be carried out in The Third Jiangyin Hospital in China and total of 120 schizophrenia patients with one negative symptom item score of PANSS≥3 will be enrolled into the study. Individu...
Eligibility Criteria
Inclusion
- Meet The Diagnostic and Statistical Manual (DSM-5) diagnostic criteria for schizophrenia;
- First onset or duration of illness less than 30 years with current symptoms in a stable condition;
- Male and female aged 18 to 50 years;
- Total score greater than or equal to 20 on the sum of the seven items constituting the Positive and Negative Syndrome Scale (PANSS) negative symptoms; an item of PANSS negative symptoms \>3 scores;
- Signed the study consent for participation.
Exclusion
- has a history of substance dependence or abuse or whose symptoms are caused by other diagnosable mental disorders;
- has a history of traumatic brain injury, seizures, or other known neurological diseases of the central nervous system;
- taking antidepressants, stimulants, mood stabilizers, or received modified electroconvulsive therapy (MECT) or rTMS during the past three months;
- having current suicidal or homicidal thoughts or any safety concern by research staff that cannot be managed during the trial;
- taking dementia-related drugs, minocycline, and other drugs that may affect cognitive function;
- Laboratory tests indicated significant abnormalities in blood routine, liver and kidney function, or other metabolic results;
- pregnant or lactating women.
Key Trial Info
Start Date :
August 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 12 2022
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT04521868
Start Date
August 31 2020
End Date
August 12 2022
Last Update
April 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Xiangya Hospital
Changsha, Hunan, China, 410008